報價延遲最少15分鐘:2025/01/12 20:43 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.53 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.40/-0.81
|
|
企業價值
23.12M
|
| 資產負債 |
|
每股賬面淨值
5.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.52
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 20:43 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline. |